A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b

Trial Profile

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs XMT 1536 (Primary)
  • Indications Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Salivary gland cancer; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Sponsors Mersana Therapeutics
  • Most Recent Events

    • 12 Dec 2017 According to a Mersana Therapeutics media release, Two expansion cohorts are expected to each enroll 30 patients with ovarian cancer and non-squamous non-small cell lung cancer, while a third cohort is expected to consist of patients with rarer tumors that are known to express NaPi2b, such as papillary thyroid cancer, papillary renal cell carcinoma, endometrial cancer and salivary duct cancer.
    • 12 Dec 2017 Status changed from not yet recruiting to recruiting, according to a Mersana Therapeutics media release.
    • 12 Dec 2017 According to a Mersana Therapeutics media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top